Tokyo Tape
Sign in
← Takeda Pharmaceutical

Quarterly report · Q2

4502.TEDINET S100PFY3
Period2022-04-01 → 2022-09-30
Filed2022-11-04
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥1.97T2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥1.00T2022-07-01 → 2022-09-30dCons.Revenue IFRS
Revenue¥3.57T2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥1.79T2021-04-01 → 2021-09-30Cons.Revenue IFRS
Revenue¥844.8bn2021-07-01 → 2021-09-30dCons.Revenue IFRS
Operating income¥255.0bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥104.4bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Operating income¥346.0bn2021-04-01 → 2021-09-30Cons.Operating profit loss IFRS
Operating income¥97.4bn2021-07-01 → 2021-09-30dCons.Operating profit loss IFRS
Profit before tax¥220.0bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥64.5bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Profit before tax¥302.6bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥284.4bn2021-04-01 → 2021-09-30Cons.Profit loss before tax IFRS
Profit before tax¥61.4bn2021-07-01 → 2021-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥166.8bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥61.7bn2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥230.1bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥183.6bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥46.0bn2021-07-01 → 2021-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥166.8bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥61.7bn2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Net income¥230.2bn2021-04-01 → 2022-03-31Cons.Profit loss IFRS (5-year summary)
Net income¥183.7bn2021-04-01 → 2021-09-30Cons.Profit loss IFRS
Net income¥46.0bn2021-07-01 → 2021-09-30dCons.Profit loss IFRS
Total assets¥14.59Tat 2022-09-30Cons.Assets IFRS
Total assets¥13.18Tat 2022-03-31Cons.Assets IFRS
Total assets¥12.56Tat 2021-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥7.88Tat 2022-09-30Cons.Liabilities IFRS
Total liabilities¥7.49Tat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥6.71Tat 2022-09-30Cons.Equity IFRS
Net assets / equity¥5.68Tat 2022-03-31Cons.Equity IFRS
Net assets / equity¥5.32Tat 2021-09-30Cons.Equity IFRS
Net assets / equity¥5.18Tat 2021-03-31dCons.Equity IFRS
Equity (owners)¥6.71Tat 2022-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥5.68Tat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Cash & equivalents¥798.1bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥849.7bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥607.9bnat 2021-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥966.2bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥305.2bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥1.12T2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥400.0bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥121.9bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥198.1bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥103.3bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥267.6bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥1.07T2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥658.4bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥107.622022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥39.772022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥147.142021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥117.082021-04-01 → 2021-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥29.242021-07-01 → 2021-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥106.882022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥39.482022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥145.872021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥116.42021-04-01 → 2021-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥29.082021-07-01 → 2021-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio46.0%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio43.1%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio42.4%at 2021-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

All source rows · 750
ItemContextValueUnit
Proceeds from sale of investments inv cf IFRSCurrentYTDDuration18400000000JPY
Acquisition of businesses net of cash and cash equivalents acquired inv cf IFRSPrior1YTDDuration-27549000000JPY
Acquisition of businesses net of cash and cash equivalents acquired inv cf IFRSCurrentYTDDuration－JPY
Proceeds from sales of business net of cash and cash equivalents divested inv cf IFRSPrior1YTDDuration2138000000JPY
Proceeds from sales of business net of cash and cash equivalents divested inv cf IFRSCurrentYTDDuration－JPY
Other inv cf IFRSPrior1YTDDuration-1292000000JPY
Other inv cf IFRSCurrentYTDDuration-609000000JPY
Net cash provided by used in investing activities IFRSPrior1YTDDuration-103349000000JPY
Net cash provided by used in investing activities IFRSCurrentYTDDuration-121920000000JPY
Net increase decrease in short term borrowings and commercial paper fin cf IFRSPrior1YTDDuration-1000000JPY
Net increase decrease in short term borrowings and commercial paper fin cf IFRSCurrentYTDDuration－JPY
Redemption of bonds and repayments of long term borrowings fin cf IFRSPrior1YTDDuration-441072000000JPY
Redemption of bonds and repayments of long term borrowings fin cf IFRSCurrentYTDDuration-26900000000JPY
Payments for purchase of treasury shares fin cf IFRSPrior1YTDDuration-2542000000JPY
Payments for purchase of treasury shares fin cf IFRSCurrentYTDDuration-26929000000JPY
Interest paid fin cf IFRSPrior1YTDDuration-52668000000JPY
Interest paid fin cf IFRSCurrentYTDDuration-52719000000JPY
Dividends paid fin cf IFRSPrior1YTDDuration-141573000000JPY
Dividends paid fin cf IFRSCurrentYTDDuration-140007000000JPY
Repayments of lease obligations fin cf IFRSPrior1YTDDuration-20536000000JPY
Repayments of lease obligations fin cf IFRSCurrentYTDDuration-20996000000JPY
Other fin cf IFRSPrior1YTDDuration-13000000JPY
Other fin cf IFRSCurrentYTDDuration-42000000JPY
Net cash provided by used in financing activities IFRSPrior1YTDDuration-658405000000JPY
Net cash provided by used in financing activities IFRSCurrentYTDDuration-267593000000JPY
Net increase decrease in cash and cash equivalents before effect of exchange rate changes IFRSPrior1YTDDuration-361743000000JPY
Net increase decrease in cash and cash equivalents before effect of exchange rate changes IFRSCurrentYTDDuration-84278000000JPY
Cash and cash equivalents IFRSPrior2YearInstant966222000000JPY
Cash and cash equivalents IFRSPrior1YearInstant849695000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1YTDDuration3402000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSCurrentYTDDuration32720000000JPY
Cash and cash equivalents IFRSPrior1QuarterInstant607881000000JPY
Cash and cash equivalents IFRSCurrentQuarterInstant798137000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2022-11-04
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第146期第２四半期(自　2022年７月１日　至　2022年９月30日)
Company name cover pageFilingDateInstant
Original text (Japanese)武田薬品工業株式会社
Company name in english cover pageFilingDateInstantTakeda Pharmaceutical Company Limited
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長CEO　　クリストフ　ウェバー
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)大阪府大阪市中央区道修町四丁目１番１号（上記は登記上の本店所在地で実際の業務は「最寄りの連絡場所」で行っております。）
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)該当なし
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)該当なし
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都中央区日本橋本町二丁目１番１号(武田薬品工業株式会社武田グローバル本社)
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京(3278)2111(代表)
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)グローバルファイナンス　チーフアカウンティングオフィサー＆コーポレートコントローラー　　竹田　徳正
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE00919
Fund codeFilingDateInstant－

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2021-07-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass